Semaglutide vs Tirzepatide: Which Is Better for Weight Loss?

The Short Answer

We now have a definitive answer. The SURMOUNT-5 trial — published May 2025 in the New England Journal of Medicine — put tirzepatide and semaglutide head to head for the first time in a large randomized study. Tirzepatide won. Patients on the highest dose lost 20.2% of body weight versus 13.7% for semaglutide at 72 weeks. Both are effective, both are FDA-approved, and both work through GLP-1 receptor activity. But tirzepatide's second mechanism gives it a clear edge on the scale.

That doesn't automatically make it the better choice for every person. Cost, insurance, side effects, and your provider's experience with each drug all factor in. And 2026 has changed the cost picture dramatically — oral Wegovy launched in January, Medicare covers Zepbound starting April, and Lilly's self-pay price has dropped. If you're comparing Ozempic vs Mounjaro or Wegovy vs Zepbound, this is the breakdown you need.

How They Work Differently

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone called GLP-1 that regulates appetite and blood sugar. When you take it, your brain gets stronger satiety signals, your stomach empties more slowly, and your insulin response improves. One target, three effects.

Tirzepatide does all of that and adds a second target. It's a dual GIP/GLP-1 receptor agonist, meaning it also activates receptors for another gut hormone called GIP (glucose-dependent insulinotropic polypeptide). GIP has its own effects on fat metabolism, insulin secretion, and how your body handles nutrients after a meal.

Think of it this way: semaglutide pulls one lever. Tirzepatide pulls two. The GIP pathway appears to amplify the appetite-suppressing and metabolic effects beyond what GLP-1 alone can do. This dual action is the main reason tirzepatide shows larger weight loss numbers in trials.

Both are available as weekly subcutaneous injections. Semaglutide now also comes as a once-daily oral pill (Wegovy 25 mg, approved December 2025 and launched January 2026). Both injectable forms require slow dose titration over several weeks to reduce GI side effects. Day to day, the experience is similar — less hunger, smaller portions, fewer food-related intrusive thoughts.

Weight Loss Results: Head to Head

We now have three data sources: the STEP trials for semaglutide, the SURMOUNT trials for tirzepatide, and — most importantly — the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in May 2025.

Semaglutide (STEP 1 trial): Participants on 2.4 mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks. About one-third lost 20% or more.

Tirzepatide (SURMOUNT-1 trial): Participants on the highest dose (15 mg) lost an average of 22.5% of body weight over 72 weeks. More than half on 10 mg or 15 mg lost 20% or more. At the 5 mg dose, the average was still 15% — roughly matching semaglutide's best result.

SURMOUNT-5 (head to head): This is the trial that settles the debate. Tirzepatide 15 mg versus semaglutide 2.4 mg, randomized, 72 weeks. Tirzepatide: -20.2% body weight. Semaglutide: -13.7%. That's a 6.5 percentage point gap. Waist circumference told a similar story — tirzepatide reduced it by 18.4 cm versus 13.0 cm for semaglutide. Both drugs worked. Tirzepatide worked more.

Oral semaglutide (OASIS 4 trial): The newly approved Wegovy pill (25 mg once daily) produced 16.6% mean body weight loss — less than injectable tirzepatide, but delivered without a needle.

Cardiovascular outcomes: A 2026 study in Nature Medicine found that both drugs show similar cardiovascular benefits in real-world populations. If heart risk reduction is your main concern, neither has a clear advantage over the other on that front.

A few things to keep in mind with these numbers. Trial participants receive structured support, regular monitoring, and lifestyle counseling that you won't get from a prescription alone. Real-world results are typically lower. Individual responses vary a lot — some people lose 25% on semaglutide, some lose 10% on tirzepatide. Averages don't tell the whole story.

Side Effects Compared

The side effect profiles overlap heavily because both drugs act on GLP-1 receptors. The most common complaints with either medication are gastrointestinal:

• Nausea
• Diarrhea
• Constipation
• Abdominal pain
• Reduced appetite (which is sort of the point)
• Vomiting

In the SURMOUNT trials, nausea affected about 24-33% of tirzepatide users depending on dose. In the STEP trials, it was around 44% for semaglutide. That's a notable difference, and some providers have observed that patients tolerate tirzepatide slightly better in terms of nausea — possibly because the GIP component smooths out some of the GLP-1 effects on the gut.

Both drugs carry a boxed warning about thyroid C-cell tumors found in rodent studies. Neither has shown this risk in humans, but both are contraindicated if you have a personal or family history of medullary thyroid carcinoma.

Pancreatitis is a rare but serious risk with both. Gallbladder issues, including gallstones, have been reported more frequently in clinical trials for both medications than in placebo groups. This risk seems tied to rapid weight loss itself rather than the drugs specifically.

The muscle loss question comes up often. Any significant calorie deficit causes some lean mass loss alongside fat loss. Neither drug is worse than the other here, but both require attention to protein intake and resistance training to preserve muscle.

Cost Comparison

This is where things get messy.

Brand-name pricing (2026): Wegovy injectable lists at roughly $1,349 per month. The new oral Wegovy pill launched in January 2026 at approximately $149 per month — a fraction of the injectable price. Zepbound (tirzepatide for weight loss) is available through LillyDirect self-pay starting at $299 per month. These prices shift, but the trend line is down.

Insurance coverage: This varies by plan, but the landscape shifted in 2026. Some commercial plans cover Wegovy or Zepbound for weight loss with prior authorization. The big change: Medicare will cover Zepbound at a maximum of $50 per month out-of-pocket starting April 2026. Many plans that cover Ozempic or Mounjaro for diabetes still won't cover the same drug for weight loss. Your provider's office can help run a benefits check.

Compounded versions: Compounded semaglutide is still available from licensed 503A and 503B pharmacies, but access has narrowed. The FDA ended the semaglutide shortage in February 2025, and grace periods for existing compounders expired in May 2025. Compounding is still legal for patient-specific prescriptions, but the supply is heavily restricted compared to a year ago. Compounded tirzepatide is effectively unavailable — the FDA ended its enforcement discretion in March 2025. If you were relying on compounded versions of either drug, talk to your provider about brand-name alternatives or the new lower-cost options above.

Manufacturer savings programs: Both Novo Nordisk and Eli Lilly offer savings cards that can reduce out-of-pocket costs for commercially insured patients. Lilly in particular has been aggressive with direct-to-consumer pricing through LillyDirect. These programs change frequently and have eligibility restrictions.

Which One Should You Ask About?

If your primary goal is maximum weight loss and your provider has experience with both drugs, tirzepatide has the stronger clinical data. The numbers are clear on that.

But "better in a trial" doesn't always mean "better for you." A few scenarios where semaglutide might make more sense: you want an oral option (the Wegovy pill launched January 2026 at ~$149/month), your insurance covers it but not tirzepatide, or you've already started semaglutide and are responding well. There's also more long-term safety data on semaglutide simply because it's been on the market longer.

The best approach is to have a direct conversation with a licensed provider who knows your medical history. Bring your questions. Ask about both options by name. A good provider will walk through the trade-offs with you rather than defaulting to one option for every patient.

If you haven't started either medication yet, it's worth getting a full workup first — metabolic panel, thyroid function, A1C — so your provider can make a well-informed decision with you.

Semaglutide vs Tirzepatide FAQs

Is tirzepatide stronger than semaglutide?

By the numbers, yes. The SURMOUNT-5 head-to-head trial confirmed it: tirzepatide produced 20.2% body weight loss versus 13.7% for semaglutide at 72 weeks. The dual GIP/GLP-1 mechanism gives tirzepatide additional metabolic effects that semaglutide's GLP-1-only approach doesn't match. That said, "stronger" depends on what you're measuring. For blood sugar control in type 2 diabetes, both are highly effective, and tirzepatide still comes out ahead in most comparisons. For cardiovascular outcomes, 2026 real-world data suggests they perform similarly.

Can you switch from semaglutide to tirzepatide?

Yes, and it's becoming a common move — especially for patients who've plateaued on semaglutide or want to try the dual-agonist approach. There's no mandatory washout period. Most providers will start tirzepatide at the lowest dose (2.5 mg) regardless of where you were on semaglutide, then titrate up on the standard schedule. Expect some return of GI side effects during the transition since the GIP component is new to your system, even if you're used to GLP-1 activity.

Which has fewer side effects, semaglutide or tirzepatide?

Clinical trial data suggests tirzepatide may cause slightly less nausea than semaglutide, which is the single most common side effect of both drugs. The overall GI side effect rates are comparable. Neither medication has a dramatically different safety profile from the other. Both require the same precautions around thyroid history, pancreatitis risk, and gallbladder issues. In practice, individual tolerance varies more than the averages would suggest — some people breeze through semaglutide and struggle with tirzepatide, and vice versa.

Is Ozempic or Mounjaro better for weight loss?

Mounjaro (tirzepatide) produces more weight loss than Ozempic (semaglutide) based on available clinical data. But there's an important wrinkle: Ozempic is technically approved for type 2 diabetes, not weight loss. The weight-loss-specific versions are Wegovy (semaglutide) and Zepbound (tirzepatide). The active ingredients are the same within each pair, but dosing and FDA indication differ. If weight loss is your primary goal, you'd want to discuss Wegovy vs Zepbound with your provider, though many patients use Ozempic or Mounjaro off-label for weight management.

Are semaglutide and tirzepatide the same thing?

No. They're different molecules made by different companies. Semaglutide is made by Novo Nordisk and activates only GLP-1 receptors. Tirzepatide is made by Eli Lilly and activates both GLP-1 and GIP receptors. They belong to the same general class of incretin-based therapies and share many of the same side effects. But they are distinct drugs with different mechanisms, different dosing schedules, and different clinical trial results. Semaglutide is now available as both a weekly injection and a daily pill. Tirzepatide remains injection-only as of 2026.